{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:33:00Z","timestamp":1790652780569,"version":"4.1.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Breast cancer (BC) chemoprevention (CP) is highly effective in reducing invasive BC risk, yet uptake among eligible women at high risk remains critically low. Prior research has not adequately examined CP decision-making alongside other primary prevention therapies, such as statins, in the practical context of multimorbidity and polypharmacy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify cognitive, emotional, and perceptual factors associated with accepting statins while declining or deferring breast cancer chemoprevention.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this exploratory qualitative study, in-depth semistructured interviews were conducted at a single academic health system between December 2024 and June 2025 with women aged 40 to 79 years at elevated risk for BC. Interviews focused on experiences with and perceptions of both BC chemoprevention and statin therapy. Analysis used an iterative, team-based thematic approach supported by a novel hybrid artificial intelligence\u2013human coding workflow.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were themes identified through thematic analysis that explain systematic differences in patient acceptance of statins and deferral of CP agents.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 17 women with high risk for BC (mean [SD] age, 54.5 [10.6] years), 3 overarching categories of themes were identified: (1) risk framing, (2) trade-offs, and (3) pathway complexity. Statins were commonly framed as routine, low-burden, measurable interventions that fit easily into a familiar model of preventive care. In contrast, CP was often perceived as a high-burden, uncertainty-heavy, identity-relevant cancer treatment with benefits experienced as probabilistic, long-term, and invisible. This asymmetry was amplified by multimorbidity and polypharmacy, contributing to treatment fatigue and fragmented clinical pathways in which statins receive clear, prescriptive guidance; however, CP is offered through nondirective, complex discussions across multiple specialists.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this qualitative study, the divergence in women\u2019s decisions about statins vs CP reflected a systematic interplay of drug-specific beliefs, emotional heuristics, and health system structures. These asymmetries may be addressed by reframing CP as a member of a family of preventive risk-reducing medications, presenting it as a reversible and time-limited trial, and embedding it in clearer, more integrated clinical communication with decision support, which may increase appropriate CP uptake among women at high risk.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.35555","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:30:38Z","timestamp":1790609438000},"page":"e2635555","source":"Crossref","is-referenced-by-count":1,"title":["Perceptions of Chemoprevention Among Women at High Risk for Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Romi","family":"Eli","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"West","sequence":"additional","affiliation":[{"name":"Fu Foundation School of Engineering and Applied Science, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa M.","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Allegrante","sequence":"additional","affiliation":[{"name":"Department of Health Studies and Applied Educational Psychology, Teachers College, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarvis J.","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Kronish","sequence":"additional","affiliation":[{"name":"Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Crew","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Kukafka","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York"},{"name":"Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"4","key":"zoi260956r1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260956r2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1056\/NEJMsr1407164","article-title":"Atypical hyperplasia of the breast\u2013risk assessment and management options.","volume":"372","author":"Hartmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi260956r3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1245\/s10434-019-07236-8","article-title":"Chemoprevention uptake for breast cancer risk reduction varies by risk factor.","volume":"26","author":"Flanagan","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"zoi260956r4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1940-6207.CAPR-22-0013","article-title":"Patient and provider web-based decision support for breast cancer chemoprevention: a randomized controlled trial.","volume":"15","author":"Crew","year":"2022","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"zoi260956r5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10865-022-00289-3","article-title":"Affect regulation as a moderator of intentions for breast cancer chemoprevention.","volume":"45","author":"Conley","year":"2022","journal-title":"J Behav Med"},{"issue":"9","key":"zoi260956r6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/jama.2019.5780","article-title":"Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"zoi260956r7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1940-6207.CAPR-20-0369","article-title":"Breast cancer chemoprevention: use and views of Australian women and their clinicians.","volume":"14","author":"Macdonald","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"zoi260956r8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1089\/jwh.2018.7643","article-title":"Breast cancer chemoprevention: a practical guide for the primary care provider.","volume":"29","author":"Farkas","year":"2020","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"zoi260956r9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12911-022-01954-y","article-title":"Qualitative analysis of shared decision-making for chemoprevention in the primary care setting: provider-related barriers.","volume":"22","author":"Jones","year":"2022","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"zoi260956r10","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/bcr3468","article-title":"Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.","volume":"15","author":"Korfage","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"1","key":"zoi260956r11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12911-018-0716-5","article-title":"Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting.","volume":"18","author":"Kukafka","year":"2018","journal-title":"BMC Med Inform Decis Mak"},{"issue":"33","key":"zoi260956r12","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline Update.","volume":"37","author":"Visvanathan","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi260956r13","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.mayocp.2017.10.001","article-title":"Use of the coronary artery calcium score in discussion of initiation of statin therapy in primary prevention.","volume":"92","author":"Michos","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"zoi260956r14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","article-title":"Sample Size in Qualitative Interview Studies: Guided by Information Power.","volume":"26","author":"Malterud","year":"2016","journal-title":"Qual Health Res"},{"issue":"4","key":"zoi260956r15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: exploring its conceptualization and operationalization.","volume":"52","author":"Saunders","year":"2018","journal-title":"Qual Quant"},{"issue":"2","key":"zoi260956r16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"issue":"1","key":"zoi260956r17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1940-6207.CAPR-25-0153","article-title":"Comparing breast cancer and cardiovascular risk among women undergoing screening mammography: why are statins more widely accepted compared with chemoprevention?","volume":"19","author":"Zeiger","year":"2026","journal-title":"Cancer Prev Res (Phila)"},{"issue":"12","key":"zoi260956r18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1940-6207.CAPR-23-0181","article-title":"Comparing breast cancer and cardiovascular disease risk and use of chemoprevention and statins among women with high-risk breast lesions.","volume":"16","author":"Lawal","year":"2023","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"zoi260956r19","doi-asserted-by":"publisher","first-page":"17014","DOI":"10.1038\/s41598-025-01930-2","article-title":"Reasons for non-acceptance of statin therapy by patients at high cardiovascular risk.","volume":"15","author":"Xie","year":"2025","journal-title":"Sci Rep"},{"issue":"14","key":"zoi260956r20","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi260956r21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1745691612460685","article-title":"Dual-process theories of higher cognition: advancing the debate.","volume":"8","author":"Evans","year":"2013","journal-title":"Perspect Psychol Sci"},{"issue":"2","key":"zoi260956r22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1037\/0033-2909.127.2.267","article-title":"Risk as feelings.","volume":"127","author":"Loewenstein","year":"2001","journal-title":"Psychol Bull"},{"issue":"6","key":"zoi260956r23","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects.","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin"},{"issue":"1","key":"zoi260956r24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41416-023-02293-z","article-title":"Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.","volume":"129","author":"Hammarstr\u00f6m","year":"2023","journal-title":"Br J Cancer"},{"issue":"7","key":"zoi260956r25","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.4028","article-title":"Why breast cancer risk by the numbers is not enough: evaluation of a decision aid in multi-ethnic, low-numerate women.","volume":"17","author":"Kukafka","year":"2015","journal-title":"J Med Internet Res"},{"issue":"4","key":"zoi260956r26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10689-024-00371-6","article-title":"Pilot study of a decision aid on BRCA1\/2 genetic testing among Orthodox Jewish women.","volume":"23","author":"Trivedi","year":"2024","journal-title":"Fam Cancer"},{"issue":"1","key":"zoi260956r27","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooaf170","article-title":"Provider and information technology operations staff perspectives on the feasibility of writing patient-generated health data into the electronic health record.","volume":"9","author":"Saiju","year":"2026","journal-title":"JAMIA Open"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854507\/eli_2026_oi_260956_1789761977.82124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:30:38Z","timestamp":1790609438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.35555","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}